Verici Dx plc
("Verici Dx" or the "Company")
Notice of Results
Investor Briefing
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it will release its unaudited results for the six-month period to 30 June 2021 on Monday 13 September 2021.
Investor briefing
Sara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live presentation relating to the Half Year Results via the Investor Meet Company platform on Monday 13 September 2021 at 16:30hrs BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00hrs the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:
https://www.investormeetcompany.com/verici-dx-plc/register-investor
Investors who already follow Verici Dx plc on the Investor Meet Company platform will automatically be invited.
Enquiries:
| Verici Dx | |
| Sara Barrington, CEO | Via Walbrook PR |
| Julian Baines, Chairman |
|
| |
|
| N+1 Singer (Nominated Adviser & Broker) | Tel: 020 7496 3000 |
| Aubrey Powell / Justin McKeegan / Tom Salvesen |
|
| |
|
| Walbrook PR Limited | Tel: 020 7933 8780 or vericidx@walbrookpr.com |
| Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 |
About Verici Dx plc www.vericidx.com
Verici Dx is developing and commercialising tests to understand how a patient will respond and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ and in conjunction with biological pathways. Our products and solutions are underpinned by extensive scientific research producing RNA signatures to determine the risk and diagnosis of acute rejection, chronic injury and ultimately failure of the transplant. These RNA signatures also provide valuable information to clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
